Skip to Content

Ryan Chirnomas focuses his practice on patent prosecution before the U.S. Patent and Trademark Office, specializing in biotechnology, pharmaceutical, chemical, and mechanical engineering inventions. Ryan uses effective communication and problem-solving skills in order to help clients obtain strong patent protection in a cost-efficient manner.  He is also experienced at the Patent Trial and Appeal Board, where he has successfully advocated for reversal of rejections in numerous ex parte oral hearings.

Ryan also provides clients with guidance by preparing freedom-to-operate, non-infringement, and validity opinions.


  • Glushko-Samuelson Intellectual Property Law Clinic, American University, Washington College of Law, 2003-2004


  • Patent Attorney – Greenblum and Bernstein, P.L.C. (2023-Present)
  • Patent Attorney – Private Practice, 2005-2023

Offices/Professional Activities

Speaking engagements:

  • “Biotech 2012: Myriad and Mayo” Japan Patent Attorneys Association, Bio-Pharma Study Group, Tokyo, Japan, 2012.
  • “AIA Provisions That Every Bio/Pharma Practictioner Should Know About”, Japan Patent Attorneys Association, Bio-Pharma Study Group, Tokyo, Japan, 2012.
  • “Biotechnology and Genetic Engineering Practice”, Japan Intellectual Property Association, Washington, D.C., 2011.
  • “Recent Developments in U.S. Biotech Patent Law 2011” Japan Patent Attorneys Association, Bio-Pharma Study Group, Tokyo, Japan, 2011.
  • “Gene Patenting: The Myriad Genetics Case” Japan Patent Attorneys Association, Bio-Pharma Study Group, Tokyo, Japan, 2010.
  • “Expedited Examination” Japan Intellectual Property Assocation, Washington, D.C., 2009.
  • “Recent CAFC Decisions” Japan Intellectual Property Association, Tokyo, Japan, 2007.

Professional Associations and Memberships


Representative Publications

  • Brandon D. Jeffy , Ryan B. Chirnomas, Eddie J. Chen, Jean M. Gudas, Donato F. Romagnolo. 2002. Activation of the aromatic hydrocarbon receptor pathway is not sufficient for transcriptional repression of BRCA-1: Requirements for metabolism of benzo[a]pyrene to 7r,8t-Dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Cancer Research 62(1):  113-121.
  • Brandon D. Jeffy, Ryan B. Chirnomas, Donato F. Romagnolo. 2002. Epigenetics of breast cancer: Polycyclic aromatic hydrocarbons as risk factors. Environmental and Molecular Mutagenesis 39(2-3):  235-244.
  • Donato F. Romagnolo, Ryan B. Chirnomas, Jennifer Ku, Brandon D. Jeffy, Claire M. Payne, Hana Holubec, Lois Ramsey, Harris Bernstein, Carol Bernstein, Kathleen S. Kunke, Achyut K. Bhattacharyya, James A. Warneke, Harinder S. Garewal.   Deoxycholate, an Endogenous Tumor Promoter and DNA Damaging Agent, Modulates BRCA-1 Expression in Apoptosis-Sensitive Epithelial Cells: Loss of BRCA-1 Expression in Colonic Adenocarcinomas.  Nutrition and Cancer. 46(1): 82-92.
  • Yuko Matsutoya, Ryan B. Chirnomas.   Are Genes Patentable?  The Myriad Case.  PharmStage Vol. 10, No. 11, p. 39-45.


  • English